Agenus' Investigational Cancer Combo Therapy Shows 33% Durable Responses In Ovarian Cancer

  • Agenus Inc AGEN announced results from a cohort of 24 evaluable patients in an expansion of its Phase 1b study of botensilimab (multifunctional CTLA-4 antibody) in combination with balstilimab (PD-1 antibody) in patients with recurrent platinum-resistant/refractory ovarian cancer. 
  • These findings showed a 33% overall response rate (ORR).
  • Other PD-(L)1 + CTLA-4 combinations in other trials reported 3-10% response rates in a comparable patient population.
  • Also Read: Agenus Presents Clinical Data Demonstrating Durable Responses For Colorectal Cancer Candidate.
  • The ovarian cancer cohort is part of a large study evaluating the safety, efficacy, and dose optimization of botensilimab alone and in combination with balstilimab in multiple solid tumors. 
  • Agenus is currently enrolling in Global Phase 2 ACTIVATE trial programs in metastatic microsatellite stable colorectal cancer, melanoma, and pancreatic cancers. 
  • Based on recent positive findings at SITC, Agenus is also expanding enrollment of its anti-PD-(L)1 relapsed/refractory non-small cell lung cancer cohort of the Phase 1b study and planning additional NSCLC studies.
  • The disease control rate was 67%, and the median duration of response was not reached, with a manageable tolerability profile.
  • Price Action: AGEN shares are up 7.05% at $1.60 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsPenny StocksHealth CareSmall CapMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!